Atlas Trials

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Clinical trial NCT00210600 · COMPLETED

Trial details

NCT number
NCT00210600
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Anemia
Start date
2005-05-01
Enrollment
186

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.